

# Left atrioventricular ratio (LA:LV): using left ventricular size as the reference for identifying maladaptive left atrial remodelling

Luke W. Spencer <sup>1,2</sup>, Sara Moura Ferreira <sup>3,4</sup>, Mauricio Milani <sup>3,5,6</sup>,  
 Stephanie J. Rowe <sup>1,2,7</sup>, Youri Bekhuis <sup>3,4,8,9</sup>, Maarten Falter <sup>3,4,9</sup>,  
 Tim Van Puyvelde <sup>1,9,10</sup>, Kristel Janssens <sup>1,11</sup>, Amy M. Mitchell <sup>1,2</sup>,  
 Paolo D'Ambrosio<sup>1,12</sup>, Boris Delpire <sup>3,4,8</sup>, Rik Pauwels <sup>3,4,8,9</sup>, Leah Wright <sup>13</sup>,  
 Erin J. Howden <sup>2,13</sup>, Guido Claessen <sup>3,4,9†</sup>, Andre La Gerche <sup>1,2,7,8,14\*†</sup>, and  
 Jan Verwerft<sup>3,4†</sup>

<sup>1</sup>Heart, Exercise and Research Trials (HEART) Lab, St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia; <sup>2</sup>Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia; <sup>3</sup>Department of Cardiology and Jessa & Science, Hartcentrum, Jessa Hospital, Hasselt, Belgium; <sup>4</sup>Faculty of Medicine and Life Sciences/LCRC, Hasselt University, Diepenbeek, Belgium; <sup>5</sup>Rehabilitation Research Center (REVAL), Faculty of Rehabilitation Sciences, Hasselt University, Hasselt, Belgium; <sup>6</sup>Health Sciences and Technologies Graduate Program, University of Brasilia (UnB), Brasilia, DF, Brazil; <sup>7</sup>Cardiology Department, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; <sup>8</sup>Department of Cardiovascular Diseases, UZ Leuven, Leuven, Belgium; <sup>9</sup>Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; <sup>10</sup>Department of Cardiology, Hartcentrum Bonheiden Lier, Bonheiden, Belgium; <sup>11</sup>Exercise and Nutrition Research Program, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia; <sup>12</sup>Department of Cardiology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; <sup>13</sup>Cardiometabolic Health and Exercise Physiology Lab, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; and <sup>14</sup>Heart, Exercise and Research Trials (HEART) Lab, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia

Received 10 April 2025; revised 7 July 2025; accepted 11 November 2025; online publish-ahead-of-print 27 November 2025

## Introduction

Remodelling of the left atrium (LA) and left ventricle (LV) occurs in response to pathological and physiological stimuli, yet their inter-dependence is often overlooked in clinical practice. The left atrioventricular ratio (LA:LV)—the ratio of maximal LA end-systolic volume (LAESV) to LV end-diastolic volume (LVEDV)—may offer valuable context for distinguishing physiological from pathological cardiac remodelling.

## Methods and results


This study evaluated LA:LV, assessed via echocardiography, and cardiorespiratory fitness assessed as peak oxygen uptake ( $\text{VO}_{2\text{peak}}$ ) in a multi-centre international cohort spanning the cardiorespiratory fitness spectrum. Exercise capacity in healthy participants was categorized by  $\text{VO}_{2\text{peak}}$  quartiles, and cardiac structural differences were analysed. Among 2943 adults (1600 healthy, 1343 pathology), healthy individuals had a median LA:LV of 0.49 [0.38, 0.61], consistent with LVEDV being roughly twice the LAESV. Pathology revealed higher LA:LV ratios [0.53 (0.38–0.75),  $P < 0.001$ ], with marked elevations amongst AF [0.60 (0.45–0.78)] and HFpEF [0.70 (0.51–0.88)]—a 30% increase vs. healthy adults. The highest indexed LA volumes occurred in the highest  $\text{VO}_{2\text{peak}}$  quartile [Q4: 36 (28–46)  $\text{mL/m}^2$ ], while the LA:LV ratio was highest in Q1 [0.53 (0.42–0.69)]. Among participants with elevated LAVi ( $\geq 34 \text{ mL/m}^2$ ), concordance with elevated LA:LV ratio ( $\geq 0.75$ ) varied markedly by fitness level: ~60% in Q1–Q2 vs. only 7% in Q4, highlighting the importance of fitness context when interpreting LA enlargement.

## Conclusion

The LA:LV ratio effectively discriminates between adaptive and maladaptive atrial remodelling. LA:LV is typically ~0.5. Lower ratios correlate with higher functional capacity and physiological remodelling, whereas ratios  $\geq 0.75$  may indicate pathological remodelling and warrant consideration of atrial pathology.

\* Corresponding author. E-mail: andre.lagerche@svi.edu.au; (Twitter): LA:LV volumetric ratio can differentiate pathological from physiological remodelling! In cases of large LA volumes, considering LV volume helps contextualize functional capacity. A critical component of assessing cardiac health and exercise, #Echocardiography #Exercise @SVIResearch @JessaZiekenhuis  
 † The authors contributed equally as a shared senior author.





**Figure 1** Study flow diagram. Study flow depicting cohort derivation from 2943 participants who underwent TTE and CPET between April 2016 and January 2024, stratified into healthy ( $n = 1600$ ) and pathology ( $n = 1343$ ) cohorts. Created in BioRender. La Gerche, A. (2025) <https://BioRender.com/kq2vp9m>.

hypothesize that a lower LA:LV ratio indicates adaptive remodelling and is associated with higher exercise capacity, whereas elevated ratios reflect maladaptive changes linked to reduced exercise tolerance and underlying cardiac pathology. By investigating the relationship between the LA:LV and  $\text{VO}_2$  peak across a diverse international cohort, spanning asymptomatic athletes to patients with heart failure with preserved ejection fraction (HFpEF), this study seeks to characterize the LA:LV ratio as potential marker for distinguishing adaptive from maladaptive cardiac remodelling.

## Methods

### Study design and population

This prospective, international multi-centre observational study included 2943 participants aged  $\geq 16$  years who underwent transthoracic echocardiography (TTE) and cardiopulmonary exercise testing (CPET) between April 2016 and January 2024 (Figure 1). Participants were identified from two primary locations: (i) Melbourne, Australia ( $n = 512$ ), including participants from Baker Heart and Diabetes Institute and St Vincent's Institute of Medical Research, Melbourne, Australia, comprising elite endurance athletes and healthy controls enrolled in prospective research protocols, including a dedicated cohort with documented AF; and (ii) Hasselt, Belgium ( $n = 2431$ ), comprising consecutive patients referred to Jessa Hospital for clinical evaluation of dyspnoea. Patients with exercise intolerance and no former clinical diagnosis were diagnosed with HFpEF based on a  $\text{H}_2\text{FPEF}$  score  $\geq 6$  or a HFA-PEFF score  $\geq 5$ . Clinical research studies were conducted in accordance with the ethical standards set forth by the Human Research Ethics Committees at the respective participating sites.

### Study cohort derivation

#### Primary analysis: complete cohort ( $n = 2943$ )

The initial characterization of the LA:LV relationship across the spectrum of cardiovascular health and disease included all individuals aged  $\geq 16$  years

with available TTE and CPET measurements. Participants were categorized into either a Pathology or Healthy cohort.

### Pathology cohort ( $n = 1343$ )

Participants were systematically categorized as having cardiac pathology sequentially based on: (i) history of ischemic heart disease or myocardial infarction ( $n = 614$ ); (ii) congenital heart disease including Fontan circulation ( $n = 9$ ); (iii) moderate or severe valvular heart disease ( $n = 86$ ); (iv) LV systolic dysfunction, defined as  $\text{LVEF} < 50\%$  ( $n = 237$ ); (v) pulmonary hypertension, defined as pulmonary artery systolic pressure  $\geq 50$  mmHg or mean pulmonary artery pressure  $\geq 35$  mmHg at rest ( $n = 59$ ); (vi) Positive HFpEF probability scores, including HFpEF with AF ( $n = 134$ ); and (vii) AF only, either documented history or detected during exercise testing ( $n = 204$ ). Sub-analysis within the Pathology cohort was performed to examine atrial-related pathology in HFpEF (group 6) and AF (group 7).

### Healthy cohort ( $n = 1600$ )


To establish normative LA:LV relationships across the spectrum of exercise capacity while minimizing confounding from pathological remodelling, we applied stringent pathological categorization. The healthy cohort of 1600 ostensibly healthy participants, including 326 endurance athletes, represents individuals free from significant structural heart disease, systolic or diastolic dysfunction, and arrhythmia, thereby providing a reference population for cardiac adaptation across varying levels of exercise capacity. The cohort was stratified into quartiles based on  $\text{VO}_2$  peak: Q1 ( $n = 400$ , lowest exercise capacity), Q2 ( $n = 400$ ), Q3 ( $n = 400$ ) and Q4 ( $n = 400$ , highest exercise capacity) to demonstrate healthy LA:LV remodelling.

### Clinical information and anthropometry

Standardized protocols were implemented across all centres for measurements and data collection procedures. Body height and weight were recorded, and body mass index (BMI) was calculated, along with BSA







**Figure 2** Distribution of left atrioventricular ratio in the complete cohort. Density plot showing the LA:LV distribution in the complete cohort ( $n = 2943$ ), comprising healthy participants ( $n = 1600$ ) and participants with cardiac pathology ( $n = 1343$ ).

**Table 1** Baseline characteristics by exercise capacity ( $\text{VO}_2$  peak) quartiles in the healthy cohort ( $n = 1600$ )

	All	Q1	Q2	Q3	Q4
<i>n</i>	1600	400	400	400	400
<b>Demographics</b>					
Sex					
Male	796 (49.8)	83 (20.8)	141 (35.2)	254 (63.5)	318 (79.5)
Female	804 (50.2)	317 (79.2)	259 (64.8)	146 (36.5)	82 (20.5)
Age, y	60 [47, 70]	71 [65, 77]	63 [56, 71]	58 [48, 65]	38 [22, 53]
<b>Anthropometric</b>					
Body weight, kg	76 [67, 86]	71 [62, 80]	76 [67, 86]	81 [70, 91]	77 [68, 86]
BMI, $\text{kg/m}^2$	25.7 [23.2, 29.3]	26.8 [23.7, 30.0]	27.1 [23.9, 30.1]	26.8 [23.9, 30.3]	23.6 [21.7, 25.9]
<b>Hemodynamic</b>					
Resting HR, bpm	70 [63, 80]	70 [62, 79]	72 [65, 79]	70 [63, 81]	70 [61, 80]
BP Sys, mmHg	136 [123, 150]	143 [132, 155]	140 [127, 153]	137 [122, 149]	126 [117, 137]
BP Dia, mmHg	79 [70, 87]	80 [73, 88]	82 [74, 90]	81 [73, 89]	71 [63, 80]
<b>Medications</b>					
Statin (%)	166 (10.4)	66 (16.5)	42 (10.5)	42 (10.5)	16 (4.0)
ACE/ARB (%)	150 (9.4)	56 (14.0)	39 (9.8)	36 (9.0)	19 (4.8)
B-blockers/CCB (%)	128 (8.0)	58 (14.5)	31 (7.8)	34 (8.5)	5 (1.2)
<b>Risk Factors</b>					
Current Smoker (%)	61 (3.8)	20 (5.0)	27 (6.8)	14 (3.5)	0 (0.0)
Ex smoker (%)	298 (18.6)	84 (21.0)	89 (22.2)	87 (21.8)	38 (9.5)
Diabetes (%)	208 (13.0)	82 (20.5)	68 (17.0)	53 (13.2)	5 (1.2)
Hypertension (%)	520 (32.5)	201 (50.2)	170 (42.5)	121 (30.2)	28 (7.0)
<b>Exercise Capacity</b>					
$\text{VO}_2$ peak, L/min	1.55 [1.13, 2.36]	0.91 [0.77, 1.03]	1.30 [1.21, 1.44]	1.86 [1.68, 2.09]	3.40 [2.80, 4.21]

Continued

**Table 1 Continued**

	All	Q1	Q2	Q3	Q4
VO <sub>2</sub> peak, mL/kg/min	20.1 [14.8, 31.0]	12.4 [10.5, 14.6]	17.4 [15.2, 19.9]	23.4 [19.9, 27.9]	45.8 [35.9, 57.8]
<b>Echocardiographic</b>					
Left Ventricular Structure					
IVSd, cm	1.0 [0.8, 1.1]	1.0 [0.9, 1.2]	1.0 [0.9, 1.1]	1.0 [0.8, 1.1]	0.9 [0.8, 1.0]
LVPWd, cm	0.9 [0.8, 1.0]	0.9 [0.8, 1.0]	0.9 [0.8, 1.0]	0.9 [0.8, 1.0]	0.9 [0.8, 1.0]
LVM, g	148 [118, 181]	133 [109, 164]	132 [108, 159]	152 [118, 181]	171 [147, 203]
LVMi, g/m <sup>2</sup>	78 [64, 92]	75 [62, 92]	72 [59, 85]	77 [62, 90]	88 [74, 101]
LVIDd, cm	4.6 [4.2, 5.1]	4.3 [4.0, 4.7]	4.4 [4.0, 4.7]	4.7 [4.3, 5.0]	5.2 [4.8, 5.6]
RWT	0.38 [0.33, 0.44]	0.41 [0.35, 0.47]	0.40 [0.34, 0.46]	0.38 [0.32, 0.45]	0.35 [0.31, 0.39]
<b>Left Atrial Structure</b>					
LAESV, mL	47 [34, 64]	41 [31, 53]	40 [32, 53]	45 [33, 58]	70 [54, 89]
LAVi, mL/m <sup>2</sup>	25 [18, 33]	24 [18, 29]	22 [17, 29]	23 [17, 30]	36 [28, 46]
LA:LV	0.49 [0.38, 0.61]	0.53 [0.42, 0.69]	0.50 [0.37, 0.62]	0.45 [0.32, 0.59]	0.48 [0.40, 0.56]
<b>Left Ventricular Volumes and Function</b>					
LVEDV, mL	96 [74, 127]	75 [63, 90]	82 [69, 100]	101 [84, 119]	145 [121, 177]
LVEDVi, mL/m <sup>2</sup>	51 [41, 65]	42 [35, 52]	45 [38, 54]	52 [44, 61]	75 [62, 90]
LVEF, %	61 [56, 66]	61 [57, 68]	63 [56, 69]	62 [57, 67]	58 [55, 63]
LV GLS	-19 [-20, -17]	-16 [-18, -14]	-18 [-21, -14]	-19 [-20, -18]	-19 [-21, -18]
<b>Diastolic Function</b>					
Mitral E-wave velocity, cm/s	62 [51, 75]	61 [52, 73]	61 [52, 73]	59 [49, 70]	69 [55, 81]
Mitral A-wave velocity, cm/s	61 [48, 76]	74 [63, 88]	68 [58, 80]	60 [48, 72]	44 [35, 54]
E/A	0.98 [0.78, 1.35]	0.80 [0.70, 1.00]	0.90 [0.72, 1.07]	0.93 [0.76, 1.26]	1.60 [1.20, 2.21]
E/e'	7.4 [6.1, 9.7]	9.8 [8.1, 12.1]	8.7 [7.4, 10.8]	7.7 [6.3, 9.4]	6.3 [5.2, 7.2]

Data is presented as the number (n) and percentage (%) or as median with interquartile range [25th percentile, 75th percentile].

Abbreviations: ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blockers; Dia, diastolic; E/A, ratio of early to late mitral inflow velocity; E/e', ratio of early mitral inflow velocity to early mitral annular velocity; HR, heart rate; IVSd, interventricular septal wall thickness at end-diastole; LA:LV, left atrioventricular ratio; LAESV, left atrial end-systolic volume; LAVi, left atrial volume indexed to BSA; LV GLS, left ventricular global longitudinal strain; LVEDV, left ventricular end-diastolic volume; LVEDVi, left ventricular end-diastolic volume indexed to BSA; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at end-diastole; LVM, left ventricular mass; LVMi, left ventricular mass indexed to BSA; LVPWd, left ventricular posterior wall thickness at end-diastole; RWT, relative wall thickness; Sys, systolic; VO<sub>2</sub> peak, peak oxygen consumption.

Using the LAVi threshold of 34 mL/m<sup>2</sup>, 54.5% ( $n = 218$ ) of Q4 participants exceeded this cutoff, compared with 16.0% ( $n = 64$ ) in Q3, 9.5% ( $n = 38$ ) in Q2, and 13.8% ( $n = 55$ ) in Q1. Conversely, when applying the LA:LV threshold of 0.75, a reverse pattern emerged: 17.8% ( $n = 71$ ) in Q1, 13.2% ( $n = 53$ ) in Q2, 7.5% ( $n = 30$ ) in Q3, and 4.2% ( $n = 17$ ) in Q4 met these criteria. Most importantly, among participants with LAVi  $\geq 34$  mL/m<sup>2</sup>, the concordance with elevated LA:LV ( $\geq 0.75$ ) varied markedly by exercise capacity. Only 7% (16/218) of Q4 participants with elevated LAVi also demonstrated elevated LA:LV, compared with 23% (15/64) in Q3, 55% (21/38) in Q2, and 62% (34/55) in Q1.


The relationship between exercise capacity and LV volumes, LA volumes and LA:LV (as a percentage) are presented altogether in Figure 5. A curvilinear relationship was observed between LA:LV and VO<sub>2</sub> peak with individuals with the lowest VO<sub>2</sub> peak demonstrating higher LA:LV, then a very weakly negative relationship between LA:LV and VO<sub>2</sub> peak. Figure 6 shows a scatterplot of the population. After adjusting for age, sex, and anthropometric differences using the Wasserman-Hansen equation (see Supplementary data online, Figure S4), the curvilinear relationship between LA:LV and exercise capacity was attenuated, showing a weak negative linear relationship between LA:LV and VO<sub>2</sub> peak.

## Structural vs. exercise remodelling and exercise capacity

To further investigate the clinical utility of LA:LV, we examined the relationship of LA:LV with GLS in 477 patients where both measurements were available (see Supplementary data online, Tables S1–3). Both LA:LV ( $r = -0.255$ ,  $P < 0.001$ ) and LV global longitudinal strain ( $r = -0.241$ ,  $P < 0.001$ ) demonstrated similar inverse correlations with VO<sub>2</sub> peak (see Supplementary data online, Figure S5). Notably, LA:LV and LV GLS were not correlated with each other ( $r = 0.030$ ,  $P = 0.52$ ), suggesting these parameters capture different aspects of cardiac remodelling. In multivariable regression analysis, both parameters remained independent predictors of exercise capacity (LA:LV:  $\beta = -1.85$ ,  $P < 0.001$ ; LV GLS:  $\beta = -0.11$ ,  $P < 0.001$ ), with the combined model explaining 11.9% of VO<sub>2</sub> peak variance compared with 6.5% and 5.8% for each parameter alone (see Supplementary data online, Table S2). The absence of multicollinearity (VIF = 1.001 for both parameters) supports their complementary nature of LA:LV.

## Sex differences in cardiac remodelling

When stratified by sex, the correlation between VO<sub>2</sub> peak and LA:LV was found to be slightly higher in females ( $r = -0.08$ ;  $P = 0.027$ )



**Figure 3** Distribution of left atrioventricular ratio across exercise capacity quartiles in the healthy cohort. Stacked density plot showing LA:LV distribution across quartiles of exercise capacity ( $\text{VO}_2$  peak) in the healthy cohort ( $n = 1600$ ). Q1 = lowest exercise capacity, Q4 = highest exercise capacity.

compared with males ( $r = -0.03$ ;  $P = 0.427$ ). However, part of this could be attributed to males demonstrating significantly greater exercise capacity, with the highest  $\text{VO}_2$  peak in males being 44% higher than the highest value observed in females. Furthermore, the female cohort demonstrated a higher prevalence of severely reduced exercise capacity, resulting in overrepresentation within the lower  $\text{VO}_2$  peak quartiles where the relationship with LA:LV exhibits a steeper, non-linear increase.

## Discussion

### Differentiating healthy and pathological remodelling


In this large, multi-centre international cohort, we observed a high prevalence of LA enlargements and examined the utility of LA:LV as a tool to differentiate between physiological and pathological atrial remodelling (Graphical Abstract). We found that LA:LV was increased in individuals with cardiac pathology, especially in conditions where disproportionate atrial remodelling might be expected, such as AF or HFpEF. Our findings also support the value of the LA:LV as a supplementary marker to contextualize LA enlargement in subjects without known cardiac pathology. In this setting, individuals with the highest exercise capacity had the largest LA volumes but normal LA:LV. Conversely, an elevated LA:LV was predominantly found among individuals with reduced exercise capacity, which could indicate maladaptive remodelling. These results highlight the importance of considering LA:LV proportionality, rather than relying solely on LA size, when assessing diastolic function and cardiovascular risk. We suggest that an LA:LV of  $\sim 0.5$  suggests physiological normalcy and found that an LA:LV cut point of 0.75 could be used as a cut-off to indicate disproportionate remodelling.

### LA:LV ratio as a contextual marker of cardiac remodelling

The strength of the LA:LV as a measurement lies in its ability to provide physiological context for cardiovascular risk stratification. Traditionally, an enlarged LA has been viewed as a surrogate marker of chronic volume overload and elevated filling pressures, with established associations to adverse outcomes such as AF, HF, and stroke. However, as observed in our study, this interpretation does not always apply in cases of ostensibly healthy remodelling, such as in endurance athletes or in pregnancy, where LA enlargement is a balanced adaptation to meet increased circulatory demands. In these cases, large LA volumes are accompanied by proportionate LV remodelling, reflected by low LA:LV. This proportionality indicates adaptive rather than maladaptive remodelling, reinforcing the notion that LA size alone does not determine clinical significance.


### LA:LV in the athlete's heart

Approximately 40% of highly trained endurance athletes have a severely dilated LA.<sup>21</sup> This falls under the spectrum of the 'athlete's heart' phenomenon, in which symmetrical enlargement of all cardiac chambers is well described. When 'indexed' to LV size, a low LA:LV reflects this physiological symmetry, highlighting enhanced flow rates and stroke volume. However, at the upper extremes of exercise capacity, there was a slightly elevated and more heterogeneous relationship with LA:LV, indicated by wider variability. Although the Healthy cohort was devised to remove overt pathology such as AF, the subtle deviation from the expected trend could suggest maladaptive remodelling in those with exceptionally high exercise capacity. These observations align with the extreme exercise hypothesis, which suggests that the upper extremes of exercise capacity may be associated with pathological outcomes, including AF.<sup>22–27</sup> A U-shaped curve has been described between exercise capacity and AF, such that AF prevalence is most common among those with the lowest and highest exercise




**Figure 4** Cardiac volumes and left atrioventricular ratio across exercise capacity quartiles in the healthy cohort. Left atrial volume index (LAVi), left ventricular end-diastolic volume index (LVEDVi), and left atrioventricular ratio (LA:LV) across exercise capacity quartiles (Q1 = lowest, Q4 = highest) in the healthy cohort ( $n = 1600$ ). Adjacent quartile comparisons: ns =  $P > 0.05$ ; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .






**Figure 5** Relationship between LA, left ventricle and exercise capacity in the healthy cohort. Loess regression analysis between left atrial volume index (LAVi), left ventricular end-diastolic volume index (LVEDVi), left atrioventricular ratio (LA:LV), and exercise capacity (VO<sub>2</sub> peak) in the healthy cohort ( $n = 1600$ ).



**Figure 6** Association between left atrioventricular ratio and exercise capacity in the healthy cohort. Log-transformed scatterplot demonstrating the inverse relationship between LA:LV and exercise capacity (VO<sub>2</sub> peak) in the healthy cohort ( $n = 1600$ ). Colours represent LA:LV percentiles.

capacity.<sup>26,28</sup> However, considering the commonality of LA enlargement in endurance athletes, largely without clinical consequences, it appears that LA volume is not the standalone driving mechanism behind an athlete's AF risk.<sup>29</sup> Historically, it has been suggested that extreme

endurance exercise may confer a cardioprotective effect against AF in females.<sup>26</sup> However, more recent evidence challenges this notion, suggesting that while female athletes may experience a lower relative risk of AF compared with their male counterparts, the risk is



**Figure 7** Clinical application of the left atrioventricular ratio in differentiating healthy cardiac adaptations and pathology. Representative echocardiographic 4-chamber views demonstrating three clinical scenarios where the LA:LV provides diagnostic value in distinguishing healthy adaptations from pathology.

nonetheless elevated compared with the general population.<sup>30,31</sup> Thus, our findings suggest that the low LA:LV of athletes indicates the adaptive nature of LA remodelling and increased LA:LV in both sexes could be suggestive of maladaptive changes.

## Abnormal LA:LV despite 'normal' LA and LV

Extensive literature links the association between chamber enlargement, both in the LA and LV, with cardiovascular events, including incident HF.<sup>5-7</sup> However, recent studies suggest that a small LV may contribute to diminished cardiac reserve and unexplained dyspnoea in some patients.<sup>32,33</sup> This oversimplification of pathophysiology, where large or small chamber volumes are viewed as inherently pathological, neglects the mechanistic context of LA and LV volume relationship. The importance of chamber proportionality is supported by evidence that hydraulic forces during diastole, generated by cross-sectional area differences between the LA and LV, facilitate LV filling.<sup>34,35</sup> This provides a compelling physiological basis for why the relationship between LA and LV sizes, whether quantified as area differences or volume ratios, may be more clinically relevant than their absolute sizes. In the absence of confounding pathology (i.e. mitral valve disease or AF being notable exceptions), LA and LV volumes are moderately collinear. However, the LV is strongly associated with  $VO_{2peak}$ , whereas the LA has a moderate association. Therefore, an individual with normal LA and LV volumes as compared to normal reference values, could still present with an elevated LA:LV, which could indicate compensatory LA hypertrophy, LV atrophy, or both.

## LA:LV and exercise capacity

Our study found that after corrections for age, sex and anthropometry, LA:LV is not a strong predictor of  $VO_{2peak}$ . This is expected due to the collinearity between LA:LV, age, sex and exercise capacity, highlighting

the functionality of LA:LV as a measurement. In the absence of valve pathology or AF, there is a tendency for symmetrical remodelling, where LA:LV remains within a narrow range. However, the variation in exercise capacity was substantial, with a 10-fold or greater difference among the cohort. Although younger, fitter individuals were more likely to have a low LA:LV and, conversely, the older individual with lower exercise capacity is expected to have a higher LA:LV, the association is insufficiently strong for LA:LV to be used as a stand-alone predictor of exercise capacity. This relationship remained consistent across genders, illustrating the utility of the LA:LV as a simple, sex-agnostic assessment of cardiac physiology.

## LA:LV vs. Alternative Left Atrial Parameters

We calculated the LA:LV using LAESV indexed to LVEDV, an approach recently validated in healthy individuals.<sup>12</sup> This approach captures maximal chamber volumes at different phases of the cardiac cycle, offering a comprehensive assessment of chamber enlargement with prognostic utility for exercise capacity. In contrast, left atrial coupling index (LACI) has been used in some prior studies, with LA end-diastolic volume (LAEDV) indexed to LVEDV,<sup>36,37</sup> measured at the same cardiac cycle timepoint of mitral valve closure. However, other work on left atrial volumetric/mechanical coupling index uses the same LACI terminology but defines it as LAVi indexed to tissue Doppler velocity at atrial contraction (LAVi/TDI-a').<sup>16</sup> This distinction emphasizes the need for standardized measurements and common terminology that balance theoretical precision with clinical accessibility. While it may seem logical to use volumes measured at the same phase of the cardiac cycle, LAESV is more readily available in clinical practice, making LA:LV a more practical tool for everyday use. Minimal LA volume measures also tend to have greater variability, which may introduce imprecision in derived ratios.<sup>38</sup> Additionally, both LA and LV strain have gained recognition as markers of cardiac function, offering insight into the pressure-volume

relationship throughout the cardiac cycle. While LA strain demonstrates predictive value for exercise capacity in clinical populations,<sup>39</sup> it correlates poorly with exercise capacity in healthy individuals.<sup>21</sup> The same findings are observed in LV strain, with elite athletes presenting with mildly lower strain values than untrained controls.<sup>40</sup> The combination of structural volume ratios alongside strain could have clinical utility and should be explored.

## Clinical implications and potential applications

The simplicity of LA:LV makes it suitable for incorporation into echocardiographic reporting templates and clinical decision-making algorithms, streamlining cardiovascular risk assessment. The LA:LV offers significant clinical utility in the following settings (Figure 7):

- (1) **Athletic Heart vs. Pathology:** In athletes, LA enlargement is a common healthy adaptation to prolonged endurance training. Our findings demonstrate that despite having larger LA volumes, athletes typically exhibit low LA:LV, supporting the notion of physiological remodeling. Elevated LA:LV in the absence of high exercise capacity may prompt further investigation into underlying pathology.
- (2) **Heart Failure with Preserved Ejection Fraction or Atrial Fibrillation:** Both HFrEF and AF are frequently associated with disproportionate LA enlargement due to diastolic dysfunction and elevated filling pressures. An elevated LA:LV in these populations could aid in risk stratification, as well as disease monitoring and management.
- (3) **Unexplained Dyspnea and Borderline LA Enlargement:** In cases where LA size is mildly elevated but clinical significance is uncertain, LA:LV can provide additional context, helping clinicians determine whether the enlargement is compensatory or indicative of early dysfunction.
- (4) **Pathological LA remodeling:** Underlying pathology is associated with pathological LA remodeling, providing further utility for LA:LV in detecting early signs of pathology and guiding clinical decision-making.

## Limitations

Our study sample was specifically designed to capture a broad spectrum of exercise capacity and extremes of chamber remodelling. The study's observational nature limits causal inference. The analysis, based on cross-sectional data, revealed variability in LA:LV across all VO<sub>2</sub> peak quartiles. Long-term studies are needed to assess the consequences of a higher LA:LV to determine whether it represents maladaptive remodelling and increased HF risk. While the inclusion of both healthy and pathological populations strengthen the findings, potential selection bias exists, particularly with the overrepresentation of athletes. Additionally, the differences between centres for posture and phenotype in both TTE and CPET introduced collinearity, preventing adjustment for these variables in our models and potentially affecting absolute measurements. Although our study highlights the diagnostic potential of the LA:LV, its prognostic utility, especially in predicting AF, HF hospitalization, or mortality, remains to be established.

## Conclusions

The LA:LV is a simple, accessible, and physiologically grounded tool for distinguishing between adaptive from maladaptive cardiac remodelling. By contextualizing LA enlargement relative to LV size, it provides valuable insights into cardiac function and exercise capacity that standalone measurements may overlook. In clinical practice, the LA:LV ratio could enhance risk stratification, particularly in populations where LA enlargement is ambiguous or confounded by physiological adaptation. Easily obtainable from routine echocardiography,

the LA:LV has broad applicability in both athletic and clinical cardiology. This study identifies a normal LA:LV as ~0.5 and LA:LV values  $\geq 0.75$  indicate disproportional remodelling and warrant consideration of atrial pathology. Future studies should explore its prognostic value and potential as a therapeutic or monitoring tool in cardiovascular disease management.

## Supplementary data

Supplementary data are available at *European Heart Journal - Cardiovascular Imaging* online.

## Author contributions

Luke W Spencer (BBiomed (Hons) (Conceptualization [equal]; Data curation [lead]; Formal analysis [lead]; Investigation [lead]; Methodology [lead]; Resources [lead]; Software [lead]; Visualization [lead]; Writing—original draft [lead]; Writing—review & editing [lead])), Guido Claessen (MD PhD (Conceptualization [supporting]; Funding acquisition [supporting]; Writing—review & editing [supporting])), Erin Howden (PhD (Conceptualization [equal]; Data curation [supporting]; Formal analysis [supporting]; Investigation [supporting]; Methodology [supporting]; Supervision [equal]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Leah Wright (PhD (Conceptualization [equal]; Investigation [supporting]; Methodology [supporting]; Supervision [equal]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Rik Pauwels (MD (Investigation [supporting]; Project administration [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Boris Delpire (MD (Data curation [supporting]; Investigation [supporting]; Writing—review & editing [supporting])), Paolo DE28099Ambrosio (MBBS (Writing—original draft [supporting]; Writing—review & editing [supporting])), Andre La Gerche (MBBS PhD (Conceptualization [equal]; Data curation [supporting]; Formal analysis [supporting]; Funding acquisition [lead]; Investigation [supporting]; Methodology [supporting]; Project administration [lead]; Supervision [lead]; Visualization [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Amy Mitchell (BBiomed (Hons) (Investigation [supporting]; Project administration [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Tim Van Puyvelde (MD (Conceptualization [supporting]; Investigation [supporting]; Project administration [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Maarten Falter (MD (Data curation [supporting]; Investigation [supporting]; Project administration [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Youri Bekhuis (MD (Data curation [equal]; Investigation [equal]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Stephanie J Rowe (MBBS (Investigation [supporting]; Project administration [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Mauricio Milani (MD PhD (Data curation [supporting]; Formal analysis [supporting]; Investigation [supporting]; Methodology [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Sara Moura Ferreira (MD (Data curation [equal]; Formal analysis [equal]; Investigation [equal]; Writing—original draft [supporting]; Writing—review & editing [supporting])), Kristel Janssens (BNurs (Investigation [supporting]; Project administration [equal]; Writing—original draft [supporting]; Writing—review & editing [supporting])), and Jan Verwerf (MD (Conceptualization [supporting]; Data curation [lead]; Investigation [lead]; Project administration [lead]; Resources [lead]; Supervision [supporting]; Writing—original draft [supporting]; Writing—review & editing [supporting]))

## Funding

This work was supported by a project grants from the National Health and Medical Research Council of Australia (NHMRC; APP1130353). L.S. and K.J. supported by an Australian Government Research Training Program Scholarship. A.M. is supported by a NHMRC postgraduate scholarship (IGNT2030942). P.D. is supported by a Royal Australian College of Physicians Research Entry Scholarship (2023RES00039), a National Health and Medical Research Council Postgraduate Scholarship (I2031119) and a National Heart Foundation of Australia PhD Scholarship (I107659). A.L.G. is supported by a National Health and Medical Research Council of Australia Investigator Grant (Level 1, APP2027105).

**Conflict of interest:** None declared.

## Data availability

The data underlying this article could be shared on reasonable request.

## References

- Thomas L, Muraru D, Popescu BA, Sitges M, Rosca M, Pedrizzetti G et al. Evaluation of left atrial size and function: relevance for clinical practice. *J Am Soc Echocardiogr* 2020;**33**: 934–52.
- Pelliccia A, Maron BJ, Paolo FMD, Biffi A, Quattrini FM, Pisicchio C et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. *J Am Coll Cardiol* 2005;**46**:690–6.
- Iskandar A, Mujtaba MT, Thompson PD. Left atrium size in elite athletes. *JACC Cardiovasc Imaging* 2015;**8**:753–62.
- Song G, Liu J, Ren W, Qiao W, Zhang J, Zhan Y et al. Reversible changes of left atrial function during pregnancy assessed by two-dimensional speckle tracking echocardiography. *PLoS One* 2015;**10**:e0125347.
- Henry WL, Morganroth J, Pearlman AS, Clark CE, Redwood DR, Itscoitz SB et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. *Circulation* 1976;**53**:273–9.
- Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. *Circulation* 1995;**92**:835–41.
- Tsang TSM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morpho-physiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *Am J Cardiol* 2002;**90**:1284–9.
- Rowe SJ, Paratz ED, Fahy L, Janssens K, Spencer LW, D'Ambrosio P et al. Small heart size and premature death in 366,484 individuals with normal ejection fraction. *JACC Adv* 2025;**4**:101444.
- Jeyapragash P, Moussad A, Pathan S, Sivapathan S, Ellenberger K, Madronio C et al. A systematic review of scaling left atrial size: are alternative indexation methods required for an increasingly obese population? *J Am Soc Echocardiogr* 2021;**34**:1067–76.e3.
- Steding K, Engblom H, Buhre T, Carlsson M, Mosén H, Wohlfart B et al. Relation between cardiac dimensions and peak oxygen uptake. *J Cardiovasc Magn Reson* 2010;**12**: 1–9.
- Prior DL, La Gerche A. The athlete's heart. *Heart* 2012;**98**:947–55.
- Sabo S, Dalen H, Nyberg J, Grenne BL, Jakobsen EO, Nes BM et al. Left atrial to ventricular volume ratio and relation to fitness, cardiovascular risk factors, and diastolic function in healthy individuals: the HUNT study. *Eur Heart J Imaging Methods Pract* 2024;**2**: qyae028.
- Barbier P, Solomon SB, Schiller NB, Gantz SA. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. *Circulation* 1999;**100**:427–36.
- Mălăescu G-G, Mirea O, Capotă R, Petrescu AM, Duchenne J, Voigt J-U. Left atrial strain determinants during the cardiac phases. *Cardiovasc Imaging* 2022;**15**:381–91.
- D'Ascenzi F, Anselmi F, Focardi M, Mondillo S. Atrial enlargement in the athlete's heart: assessment of atrial function may help distinguish adaptive from pathologic remodeling. *J Am Soc Echocardiogr* 2017;**31**:148–57.
- Benfari G, Essayagh B, Nistri S, Maalouf J, Rossi A, Thapa P et al. Left atrial volumetric/mechanical coupling Index. *Circ Cardiovasc Imaging* 2021;**14**:e011608.
- Lang RM, Badano LP, Mor-Avi V, Afkalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. *Eur Heart J Cardiovasc Imaging* 2015;**16**:233–70.
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr* 2016;**29**:277–314.
- Verwerf J, Bertrand PB, Claessen G, Herbots L, Verbrugge FH. Cardiopulmonary exercise testing with simultaneous echocardiography: blueprints of a dyspnea clinic for suspected HFpEF. *JACC Heart Fail* 2023;**11**:243–9.
- Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L et al. EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Circulation* 2012;**126**:2261–74.
- Spencer L, Wright L, Foulkes SJ, Rowe SJ, Dillon HT, Climie R et al. Characterizing the influence of cardiorespiratory fitness on left atrial size and function in the general population. *Am J Physiol Heart Circ Physiol* 2024;**326**:H1269–H78.
- Heidbüchel H, Anné VV, Willems R, Adriaenssens B, Van de Werf F, Ector H. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. *Int J Cardiol* 2006;**107**:67–72.
- Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. *Eur Heart J* 2008;**29**:71–8.
- Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. *Europace* 2008;**10**:15–20.
- Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaëlsson K et al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. *Eur Heart J* 2013;**34**:3624–31.
- Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK biobank cohort. *Eur Heart J* 2020;**41**:1479–86.
- Flannery MD, Canovas R, Janssens K, Mitchell AM, D'Ambrosio P, Spencer LW et al. Atrial fibrillation in former world-class rowers: role of environmental and genetic factors. *Eur Heart J* 2025;ehaf369.
- La Gerche A, Schmied CM. Atrial fibrillation in athletes and the interplay between exercise and health. *Eur Heart J* 2013;**34**:3599–602.
- Trivedi SJ, Claessen G, Stefani L, Flannery MD, Brown P, Janssens K et al. Differing mechanisms of atrial fibrillation in athletes and non-athletes: alterations in atrial structure and function. *Eur Heart J Cardiovasc Imaging* 2020;**21**:1374–83.
- Drca N, Larsson SC, Grannas D, Jensen-Urstad M. Elite female endurance athletes are at increased risk of atrial fibrillation compared to the general population: a matched cohort study. *Br J Sports Med* 2023;**57**:1175–9.
- Myrstad M, Johansen KR, Sørensen E, Løchen M-L, Ranhoff AH, Morseth B. Atrial fibrillation in female endurance athletes. *Eur J Prev Cardiol* 2024;**31**:e27–9.
- Rowe S, L'Hoyes W, Milani M, Spencer L, Foulkes S, Paratz E et al. Left ventricular volume as a predictor of exercise capacity and functional independence in individuals with normal ejection fraction. *Eur J Prev Cardiol* 2024;zwae363.
- Foulkes SJ, Howden EJ, Dillon HT, Janssens K, Beaudry R, Mitchell AM et al. Too little of a good thing: strong associations between cardiac size and fitness among women. *JACC Cardiovasc Imaging* 2023;**16**:768–78.
- Soundappan D, Fung ASY, Loewenstein DE, Playford D, Strange G, Kozor R et al. Decreased diastolic hydraulic forces incrementally associate with survival beyond conventional measures of diastolic dysfunction. *Sci Rep* 2023;**13**:16396.
- Edlund J, Östenson B, Heiberg E, Arheden H, Steding-Ehrenborg K. Exercise cardiovascular magnetic resonance shows improved diastolic filling by atrioventricular area difference in athletes and controls. *J Appl Physiol (1985)* 2024;**137**:1554–62.
- Pezel T, Venkatesh BA, De Vasconcellos HD, Kato Y, Shabani M, Xie E et al. Left atrio-ventricular coupling Index as a prognostic marker of cardiovascular events: the MESA study. *Hypertension* 2021;**78**:661–71.
- Fortuni F, Biagioli P, Myagmadorj R, Mengoni A, Chua A, Zuchi C et al. Left atrioventricular coupling Index: a novel diastolic parameter to refine prognosis in heart failure. *J Am Soc Echocardiogr* 2024;**37**:1038–46.
- Smiseth OA, Larsen CK, Hopp E. Left atrial volume as risk marker: is minimum volume superior to maximum volume? *Eur Heart J Cardiovasc Imaging* 2024;**25**:1575–6.
- Maffei C, Rossi A, Cannata L, Zocco C, Belyavskiy E, Radhakrishnan AK et al. Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction. *ESC Heart Fail* 2022;**9**:842–52.
- Caselli S, Montesanti D, Autore C, Di Paolo FM, Pisicchio C, Squeo MR et al. Patterns of left ventricular longitudinal strain and strain rate in Olympic athletes. *J Am Soc Echocardiogr* 2015;**28**:245–53.